Taksta

Short description: Oral dosing drug regimen

| This chemistry needs to be updated. Please update this chemistry to reflect recent events or newly available information. (August 2023)

|

Taksta (previously CEM-102) is a front-loaded[clarification needed] oral dosing regimen of sodium fusidate under development in the U.S. as an antibiotic for gram-positive infections including drug-resistant strains such as methicillin-resistant Staphylococcus aureus.[1]

## Clinical trials

Jan 2010: Taksta has completed enrollment in a phase 2 trial (due to run until March 2010) and is preparing for phase 3 studies in the U.S. for acute bacterial skin structure infections (being compared with linezolid).[2]

Sep 2010: Taksta demonstrated comparable clinical success rates compared to linezolid in a phase 2 trial in the U.S. for acute bacterial skin and skin structure infections.[3]

Jun 2011: Taksta may be effective in the treatment of chronic prosthetic joint infections and osteomyelitis.[4]

Dec 2015: Cempra doses first patient in a phase 3 clinical trial of Taksta in acute bacterial skin and skin structure infections.[5]

Nov 2016: Cempra completes a phase 3 clinical trial of Taksta in acute bacterial skin and skin structure infections. Results remain pending.[6]

Feb 2017: Cempra achieves the primary endpoint of a 10% non-inferiority margin. The microbiological success in each ME[clarification needed] population with methicillin-resistant S. aureus infection is 100 percent (99/99) at both the EOT[clarification needed] and PTE[clarification needed] visits.[7]

## See also

* Fusidic acid, licensed for some decades outside the US and is in clinical development in the U.S.

## References

1. ↑ "Cempra Announces Expansion of Clinical Management Team to Advance Leading Antibacterial Clinical Programs Taksta and CEM-101". http://www.earthtimes.org/articles/show/cempra-announces-expansion-of-clinical,1234560.shtml.
2. ↑ "Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections". 15 April 2019. http://clinicaltrials.gov/ct2/show/NCT00948142.
3. ↑ Craft JC, Moriarty SR, Clark K, Scott D, Degenhardt TP, Still JG, Corey GR, Still JG, Das A, Fernandes P (2011). "A randomized, double-blind Phase 2 study comparing the efficacy and safety of an oral fusidic acid loading-dose regimen to oral linezolid in the treatment of acute bacterial skin and skin structure infections." Clinical Infectious Diseases 52 (Supplement 7):S520-S226.
4. ↑ Wolfe CR. (2011) "Case report: treatment of chronic osteomyelitis." Clinical Infectious Diseases 52(Supplement 7):S538-S541.
5. ↑ "Cempra Doses First Patient in Phase 3 Clinical Trial of Taksta in Acute Bacterial Skin and Skin Structure Infections" (in en). December 8, 2015. http://investor.cempra.com/releasedetail.cfm?releaseid=946010.
6. ↑ "Oral Sodium Fusidate (CEM-102) Versus Oral Linezolid for the Treatment of Acute Bacterial Skin and Skin Structure Infections". FDA. https://clinicaltrials.gov/ct2/show/study/NCT02570490. Retrieved 17 December 2016.
7. ↑ "Cempra's Fusidic Acid Achieves Primary Endpoint in Phase 3 Study of ABSSSI". Cempra. http://investor.cempra.com/releasedetail.cfm?ReleaseID=1014395. Retrieved 4 April 2017.

0.00

(0 votes)

Original source: https://en.wikipedia.org/wiki/Taksta. Read more

|

Retrieved from "https://handwiki.org/wiki/index.php?title=Chemistry:Taksta&oldid=4177886"